摘要
甲状腺癌是全球增长速度最快、最常见的内分泌肿瘤。对于部分甲状腺癌患者,手术和放疗难以取得满意的疗效,原因可能在于肿瘤与周围免疫微环境相互作用介导了肿瘤免疫逃逸的发生。不同类型的甲状腺癌对免疫检查点抑制剂(ICIs)治疗的受益情况存在较大差异,侵袭性较高的甲状腺髓样癌和间变性甲状腺癌对程序性细胞死亡受体1/程序性细胞死亡配体1抑制剂有较好的反应率,对于晚期甲状腺乳头状癌和滤泡性甲状腺癌ICIs的效果有限,但ICIs与其他靶向药物联用可改善患者的预后。因此,未来的研究重点应为提高ICIs的疗效及开发更高效的免疫抑制剂靶点。
Thyroid cancer is the fastest growing and most common endocrine tumor in the world.For some thyroid cancer patients,surgery and radiation therapy are difficult to achieve satisfactory results,which may be due to the occurrence of tumor immune escape mediated by the interaction between the tumor and the surrounding immune microenvironment.The benefits of different types of thyroid cancer for immune checkpoint inhibitors(ICIs)treatment vary greatly,with more aggressive medullary thyroid cancer and anaplastic thyroid cancer having a better response rate to programmed cell death receptor 1/programmed cell death-ligand 1 inhibitors,but limited efficacy for advanced papillary thyroid carcinoma and follicular thyroid cancer.ICIs in combination with other targeted agents can improve the patient outcomes.Therefore,future research should focus on improving the efficacy and safety of ICIs and developing other more efficient immunosuppressive targets.
作者
贾筱夏
常莹
杜岚
马佳
任嘉铭
符颖
杨敬春
JIA Xiaoxia;CHANG Ying;DU Lan;MA Jia;REN Jiaming;FU Ying;YANG Jingchun(Department of Ultrasound Diagnosis,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)
出处
《医学综述》
CAS
2023年第1期74-79,共6页
Medical Recapitulate
基金
北京市科技计划项目(Z161100000116060)。
